Dosing

Zepbound Dosage Guide: Titration Schedule and Tips

GLP-1 Companion · 8 min read

Zepbound (tirzepatide) is FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition. It is a dual GIP and GLP-1 receptor agonist — meaning it activates two incretin hormone receptors simultaneously — which contributes to its robust weight loss efficacy seen in the SURMOUNT clinical trial program. Like all GLP-1 class medications, it follows a gradual titration schedule to minimize GI side effects.

The Complete Zepbound Titration Schedule

Zepbound is initiated at 2.5 mg weekly and escalated in 2.5 mg increments every four weeks until reaching the maintenance dose. The schedule has up to six steps, though not all patients need to reach the maximum dose.

Step 1: 2.5 mg Weekly (Weeks 1-4) — Starting Dose Only

The 2.5 mg starting dose is important to understand clearly: it is a tolerability dose, not a therapeutic dose. The SURMOUNT-1 trial and prescribing information both indicate that 2.5 mg is used only to initiate treatment and allow GI adaptation. Patients should not expect meaningful weight loss at this dose, and the lack of appetite suppression at 2.5 mg is expected and normal. This phase is about getting your body ready for the actual treatment doses.

Step 2: 5 mg Weekly (Weeks 5-8) — First Therapeutic Dose

The 5 mg dose is the first dose with demonstrated therapeutic weight loss effect. At this level, patients typically begin experiencing meaningful appetite suppression, reduced food noise, and the early stages of weight loss. GI side effects — primarily nausea, but also possible constipation or diarrhea — may increase during the transition from 2.5 mg to 5 mg. Most patients adapt within 1-2 weeks.

Step 3: 7.5 mg Weekly (Weeks 9-12)

Weight loss typically accelerates through this phase. The 7.5 mg dose produces increasingly significant GIP and GLP-1 receptor activation. Many patients find that their appetite regulation becomes substantially more stable at this level compared to lower doses.

Step 4: 10 mg Weekly (Weeks 13-16)

The 10 mg dose represents a middle range with strong efficacy data from the SURMOUNT-1 trial. In the trial, patients on 10 mg achieved approximately 19.5% body weight reduction over 72 weeks — a substantial and clinically meaningful result. Some patients and prescribers choose to maintain at 10 mg if tolerance or response is optimal at this level.

Step 5: 12.5 mg Weekly (Weeks 17-20)

The penultimate dose step. By this point, most patients have been on tirzepatide for four or more months and have developed good tolerance. GI side effects at escalation steps tend to be milder later in treatment as the body has adapted to the mechanism of action.

Step 6: 15 mg Weekly (Week 21 Onward) — Maximum Maintenance Dose

The 15 mg dose is the highest approved dose for Zepbound and the one associated with the most dramatic weight loss outcomes in clinical trials. SURMOUNT-1 data showed that patients on 15 mg achieved an average of 20.9% body weight reduction over 72 weeks. However, not every patient needs or tolerates 15 mg. The appropriate maintenance dose is the highest dose the patient tolerates that achieves their clinical goals.

SURMOUNT Trial: What the Data Shows

The SURMOUNT-1 trial enrolled 2,539 adults with obesity or overweight with weight-related complications. After 72 weeks, the dose-response data was striking.

• 5 mg dose: average weight reduction of approximately 15.0% of body weight
• 10 mg dose: average weight reduction of approximately 19.5% of body weight
• 15 mg dose: average weight reduction of approximately 20.9% of body weight
• Placebo: average weight reduction of approximately 3.1%
• These results are substantially larger than those seen with semaglutide 2.4 mg in the STEP-1 trial (approximately 14.9%)
• Approximately one-third of patients on 15 mg lost more than 25% of body weight

Not Everyone Reaches 15 mg

The titration schedule is a target, not a requirement. Many patients achieve excellent weight loss results at 5 mg, 7.5 mg, or 10 mg and may not need to continue escalating. Others may tolerate escalation well but find that the incremental benefit of the higher doses is small relative to their goals. The prescriber and patient make the escalation decision together based on ongoing response and tolerability.

Dose Holds for Intolerance

If you are experiencing significant side effects at any dose level, a dose hold — remaining at the current dose for an additional 4 weeks before attempting the next escalation — is an appropriate and common clinical strategy. Do not push through severe GI symptoms, as this is the primary driver of early treatment discontinuation.

• Dose holds are explicitly supported by the prescribing information.
• Remaining at a well-tolerated lower dose for 4-8 extra weeks before escalating is a legitimate approach.
• If a higher dose produces intolerable side effects, stepping back to the previous dose is appropriate.
• Communicate all dose changes or holds with your prescriber — do not adjust independently.

Missed Dose Rules for Zepbound

Zepbound shares the same missed dose protocol as Mounjaro, which uses the same active ingredient (tirzepatide). The window is slightly shorter than semaglutide medications, reflecting tirzepatide's pharmacokinetic profile.

• If 4 or fewer days (up to 96 hours) have passed since the missed dose: Inject as soon as you remember, then resume your regular weekly schedule from the new date.
• If more than 4 days have passed: Skip the missed dose entirely. Do not take a late dose. Resume on your next regularly scheduled injection day.
• Never take two doses in the same week to compensate for a missed injection.
• If multiple doses are missed, contact your prescriber — you may need to re-titrate to avoid a resurgence of side effects.

Zepbound vs Mounjaro: Same Drug, Different Indication

Zepbound and Mounjaro contain identical active ingredients (tirzepatide) at identical doses and use identical auto-injector pens. Mounjaro is approved for type 2 diabetes management; Zepbound is approved for chronic weight management. The titration schedules are the same. Insurance coverage differs — Mounjaro may be covered for diabetes patients, while Zepbound has its own coverage pathway for obesity. Your prescriber determines which brand is appropriate for your situation.

Zepbound's titration schedule asks for patience — five months to reach the maximum dose. But the SURMOUNT data shows that the results are worth it for patients who stay the course. Communicate with your prescriber at every step, and remember that dose holds are not failures — they are a built-in part of how this medication is designed to be used.

Sources

• Zepbound (tirzepatide) Prescribing Information. Eli Lilly.
• Jastreboff et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. NEJM.